A smaller, earlier-stage experiment
SYNERGY-NASH was a randomized, masked phase 2 trial in 190 participants with biopsy-confirmed MASH and stage F2 or F3 fibrosis. It compared three weekly tirzepatide target doses with placebo for 52 weeks. The main endpoint was MASH resolution without worsening fibrosis. Eli Lilly funded the study. [1]
Phase 2 and dose-finding describe the study’s role in development. They should remain visible when the result is discussed outside a journal. Evidence can be promising without answering all the questions a later, larger or longer study is intended to resolve.
What happened at the biopsy endpoint
MASH resolution without worsening fibrosis occurred in 44%, 56% and 62% of the tirzepatide groups, compared with 10% with placebo. Evaluable week-52 biopsies were available for 157 participants, and the analysis used assumptions for missing values. Gastrointestinal events were the most common adverse events, generally mild or moderate. [1]
The missing-biopsy issue is a useful reminder that a study result may involve both observed measurements and statistical handling of absent measurements. That does not automatically invalidate the estimate. It does mean that the methods deserve attention before a percentage is treated as a simple count of every original participant.
Keep the endpoint narrower than the headline
The primary outcome combined resolution of one feature with no worsening of another. It is more precise than saying the liver was cured. It also does not measure every future consequence of liver disease or establish a long-term clinical-event benefit by itself.
The three active groups should not be read as a personal dose menu. Dose-finding research helps characterize an intervention under a protocol; choosing treatment requires an individual clinical assessment. A reader should not infer that the group with the highest percentage is the appropriate target for them.
The presence of several target-dose groups also divides a modest trial into smaller comparisons. That should temper very precise claims about differences among active doses. The main evidence is the prespecified comparison against placebo; a confident ranking within the active groups would need its own justified statistical assessment.
Compare research maturity before comparing medicines
Our ESSENCE review covers a later-phase semaglutide study with its own population, duration and endpoint analysis. Lining up the two percentages cannot establish which medication is superior. A proper comparison would need to address those differences or directly randomize the drugs.
For a patient conversation, ask what the clinician can conclude from this study and what remains uncertain. Keep specialist liver assessment central if that is the condition being treated. Our trial-reading guide helps distinguish a study’s result from the larger claim an advertisement may build around it.